Neurochlore’s goal is to understand and treat developmental brain disorders in the basis of regulating chloride homeostasis.

Neurochlore is developing new therapeutic approaches to ameliorate neurological and psychiatric diseases based on the regulation of the brain’s electrical activity, notably modulating intracellular chloride. Located at the Institute de Neurobiologie de la Mediterranee (INMED) founded by Dr. Ben-Ari, who is Honorary Director and Co-Team Leader at INMED, Neurochlore is surrounded by internationally recognized scientific experts in all fields of developmental neurobiology and neurological disorders. Extensive collaborations with drug developers and clinical experts in neuropediatrics ans psychiatry enables Neurochlore to develop and test novel therapeutic agents. Neurochlore has an international patent in the use of a diuretic, an antagonist of the NKCC1 chloride co-transporter, in the treatment of autism spectrum disorders and developmental brain disorders.

Access to Neurochlore website